Progesterone receptor agonists and antagonists

被引：6

作者：

Allan, G ^{[1
]}

Macielag, M ^{[1
]}

机构：

[1] RW Johnson Pharmaceut Res Inst, Raritan, NJ 08869 USA

来源：

EXPERT OPINION ON THERAPEUTIC PATENTS | 1999年 / 9卷 / 07期

关键词：

contraception; endometriosis; leiomyomata; mifepristone; progestin;

D O I：

10.1517/13543776.9.7.955

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Steroidal progestin agonists have long been used in oral contraceptives, and the progestin antagonist mifepristone is used as an abortifacient. Progestin antagonists are also likely to be useful for treating breast cancer and various gynaecological disorders. This patent review relates to progestin receptor agonists and antagonists, focusing on applications filed over the past three years. Two emerging themes will be elaborated upon: the development of novel steroidal and non-steroidal compounds, and the elucidation of new therapeutic uses for progestin antagonists.

引用

页码：955 / 962

页数：8

共 20 条

[11] Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: A National Cancer Institute of Canada Clinical Trials Group Study [J].

Perrault, D ;

Eisenhauer, EA ;

Pritchard, KI ;

Panasci, L ;

Norris, B ;

Vandenberg, T ;

Fisher, B .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (10) :2709-2712

[12]

PHILIBERT D, 1984, 8 INT C PHARM

[13]

Philibert D, 1984, ADRENAL STEROID ANTA, P77

[14]

ROMIEU G, 1987, B CANCER, V74, P455

[15]

Spitz IM, 1996, ANNU REV PHARMACOL, V36, P47

[16]

TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315

[17]

VANLOOK PFA, 1989, OXFORD REV REPROD B, V11, P1

[18]

WEBB AM, 1998, BRIT MED J, V305, P927

[19] Atomic structure of progesterone complexed with its receptor [J].

Williams, SP ;

Sigler, PB .

NATURE, 1998, 393 (6683) :392-396

[20]

WOLF JP, 1989, FERTIL STERIL, V52, P1055

← 1 2 →